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Recent outbreaks of scarlet fever [1], and
increased maternal deaths due to invasive
streptococcal disease [2] are poignant re-
minders that group A Streptococcus
(GAS) remains a global threat to human
health. Thankfully, GAS remains sus-
ceptible to penicillin, which is usually
sufﬁcient for the majority of patients in-
fected with GAS. However, what to do in
the minority of patients who develop se-
vere invasive GAS (iGAS), typiﬁed by
streptococcal toxic shock syndrome
(STSS) and necrotizing fasciitis, remains
an enigma. The questions facing treating
physicians are what adjunctive therapy
should be administered, and at what
point during the course of the illness?
Two particular therapies for severe
iGAS infection have been debated over
the last 2 decades: clindamycin and intra-
venous immunoglobulin (IVIG). The
other area of ambiguity is whether clini-
cians should provide antibiotics for
close contacts of patients with iGAS. Sec-
ondary iGAS may have devastating con-
sequences; however, there is much
variation in the recommendations for an-
tibiotic prophylaxis. A study by Carapetis
et al [3], in the current issue of Clinical
Infectious Diseases, hopes to clarify these
controversies. The authors admirably set
out to answer 3 questions: (1) Does the
addition of clindamycin to a β-lactam
antibiotic improve mortality? (2) Does
additional IVIG improve mortality? (3)
Does the risk of secondary iGAS in
close contacts justify use of prophylaxis?
The mortality from severe iGAS associat-
ed with shock, even when penicillin is used,
is reported to be between 30% and 80%,
with notable international variation [4–6].
Clindamycin has been shown in vitro to in-
hibit synthesis of streptococcal superanti-
gens that circulate in STSS [7], and in a
mousemodel of GASmyositis, clindamycin
enhanced survival of animals [8]. However,
human clinical studies have been limited to
retrospective case analyses with their inher-
ent bias. These have demonstrated either
favorable outcomes associated with clinda-
mycin treatment in iGAS [9] and necro-
tizing fasciitis [10], or, alternatively, no
association between clindamycin use and
survival [11].
Intravenous human immunoglobulin is
able to neutralize circulating superantigens
and enhance bacterial clearance [12], pro-
viding a rationale for its use in STSS. Con-
cerns regarding biological safety and cost
have limited IVIG supply in countries such
as the United Kingdom and, in contrast
to other indications such as immune
thrombocytopenic purpura, there are no
adequately powered trials supporting
IVIG use in STSS. One multicenter,
randomized, double-blind, placebo-
controlled trial failed to recruit sufﬁcient
patients and, due in part to an unexpect-
edly low mortality rate in the control arm,
was underpowered to achieve statistically
meaningful outcome data [13]. Inherent
logistical difﬁculties of trials for rapidly
fatal but rare acute infections mean that
observational studies could provide the
best evidence. One cohort study reported
signiﬁcantly reduced mortality in STSS
patients treated with IVIG, but used his-
torical controls with high mortality [4]. A
more recent retrospective analysis fo-
cused on children with a control mortal-
ity of only 4.5%, suggesting that patients
may have been at the less severe end of
the iGAS spectrum [14].
The data presented in the current study
appear to favor the2 interventions,with an
odds ratio of 0.28 (95% conﬁdence in-
terval [CI], .10–.80) in favor of clindamy-
cin, and an odds ratio of 0.12 (95% CI,
.01–1.05) in favor of IVIG in addition to
clindamycin. However, as the study was
based on a ﬁxed period of active surveil-
lance in the state of Victoria in Australia
undertaken 10 years ago [15], it lacks the
power to unequivocally answer these
questions.
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Duringthegroup’searlieranalysis, cases
of iGAS were ascertained prospectively
from an extensive network of laborato-
ries, hospitals, and primary care practi-
tioners [15]. For the recent study, cases
of severe iGAS were identiﬁed by the in-
vestigators from submitted data collec-
tion forms, although investigators relied
on treating clinicians to diagnose severe
iGAS cellulitis and necrotizing fasciitis,
potentially leading to over- or underre-
porting of cases. Furthermore, any effect
of polymicrobial involvement in these 2
conditions would be difﬁcult to deter-
mine. Eighty-four patients with severe
iGAS were identiﬁed, and 63% were ad-
mitted to a major teaching hospital.
Whether these patients were de novo
admitted to a teaching hospital or trans-
ferred due to severity of disease requiring
further specialist input is unstated. How-
ever, once at the teaching hospital, pre-
sumably being treated by infection
specialists, patients were signiﬁcantly
more likely to receive clindamycin. This
is unsurprising, as surveys suggest that
clindamycin is generally recommended
by infectious disease physicians for pa-
tients with severe iGAS, despite the limit-
ed evidence [16].
Patients treated with clindamycin had
half the mortality rate compared with pa-
tients who did not receive clindamycin,
and the authors observe that this is de-
spite clindamycin-treated patients having
more severe disease, as judged by STSS,
admission to the intensive care unit
(ICU), and length of stay. This observa-
tion should be interpreted with caution.
First, although STSS was used as a marker
of severity, the inclusion of rash and soft
tissue necrosis as potential STSS criteria
means that a diagnosis of STSS does not
necessarily indicate additional organ
dysfunction. Second, the clindamycin-
treated patients were of signiﬁcantly
younger age, a known predictor of im-
proved survival in iGAS [5, 6, 11]; indeed,
86% of fatalities in the current study were
among patients aged ≥60 years. ICU ad-
mission and length of stay may be less
reliable markers of disease severity than
objective physiological scoring systems.
Instead, they may represent markers of
early severe sepsis recognition, comorbid-
ities, or interventions, which are in-
dependent of initial disease severity.
Older age may be a barrier to ICU admis-
sion, if perceived as a predictor of poorer
outcome, additionally the association be-
tween clindamycin administration and
pseudomembranous colitis may inﬂuence
the prescribing behavior of clinicians,
leading to potential bias if older patients
do not receive this drug.
The authors adjust for these confound-
ing factors (age ≥60 years, STSS, type of
hospital, and ICU admission) in multivar-
iate analysis, and although the odds ratios
remained suggestive of a beneﬁt from clin-
damycin treatment, all the 95% CIs stub-
bornly crossed 1.0. Hence, the effect of
adjunctive clindamycin therapy on mor-
tality, independent of treatment decisions
based on individual patient factors such
as age, still lacks clarity. Perhaps a case-
control study design with groups matched
for age and disease severity at presentation
would have helped to address this prob-
lem. Furthermore, no mention is made
of the impact of surgery in addition to
clindamycin, or the timing of initiation
of antimicrobial therapy, both of which
are factors that may inﬂuence outcome.
Whereas the statistical interpretation
of the role of clindamycin on outcome
may be hindered by a number of con-
founding factors, the small number of pa-
tients (n = 14) receiving IVIG in this
study strikingly limits this part of the
analysis. It has been calculated that a
sample size of 70 would be required to
achieve a statistically signiﬁcant mortality
reduction from 60% to 40% [16]. Perhaps
inevitably, only patients receiving clinda-
mycin were treated with IVIG, thus mak-
ing it difﬁcult to clearly deﬁne the
independent beneﬁt of IVIG. Indeed, at
the time of the original study, IVIG was
not easily available in Victoria [15].Nota-
bly, IVIG-treated patients were less likely
to be immunocompromised or have an
underlying chronic condition, suggesting
an inherent bias in the patients selected to
receive this adjunctive therapy. These fac-
tors may inﬂuence the case fatality rate;
chronicmedical conditions adversely effect
outcome in severe GAS infections [5].
In a separate analysis, the investigators
report an incidence rate of secondary
iGAS that is >2000-fold higher among
household contacts than among the gene-
ral population, favoring the use of anti-
biotic prophylaxis. The investigation
required enumeration of total household
contacts at risk, identiﬁed via a retrospec-
tively administered postal questionnaire.
Although undoubtedly an impressive un-
dertaking, the exclusion criteria for the
questionnaires meant that only 95 re-
sponses (38%) were received from the
251 index patients who had been living
at home. Extrapolating the mean number
of household contacts per index patients
from the subset that responded resulted
in a calculated risk ratio with a very wide
95% CI (413–5929). This imprecision is
perhaps expected, as there was a range of
0–12 household contacts per index patient
from questionnaire responders. Whether
antimicrobial prophylaxis can reduce
household risk remains unknown. Al-
though it has been administered in some
countries, the resulting beneﬁt has not
been reported, and the optimum choice
and duration of antimicrobial are unclear.
Although this study is certainly not de-
ﬁnitive, it adds to the growing literature
that supports use of clindamycin in se-
vere iGAS; however, the adjunctive role
of IVIG remains unclear, although there
is some suggestion of beneﬁt. Increasing
clindamycin resistance observed in recent
outbreaks [1] may limit the relevance of
this study in some regions, necessitating
evaluation of alternative protein synthesis
inhibitors. While infectious disease spe-
cialists appear to have the appetite for a
properly controlled trial of IVIG [16], the
daunting number of patients neededwould
require a truly global effort and be techni-
cally challenging. Instead, accumulating
evidence from commendable studies such
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as this will be required to inform our treat-
ment decisions in severe iGAS.
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